FDA com­mis­sion­er hints at car­dio-re­lat­ed la­bel ex­pan­sion for We­govy, full ap­proval for Lil­ly's new Alzheimer's drug

WASH­ING­TON — FDA Com­mis­sion­er Rob Califf took the podi­um Wednes­day af­ter­noon at the Na­tion­al Press Club, of­fer­ing up more warn­ings about mis­in­for­ma­tion lead­ing to de­clin­ing vac­cine up­take, and his usu­al quips about de­clin­ing life ex­pectan­cy.

But he al­so hint­ed at two up­com­ing mile­stones: an ex­pand­ed la­bel for No­vo Nordisk’s GLP-1 ag­o­nist We­govy (semaglu­tide) that fea­tures its car­dio­vas­cu­lar ben­e­fits, and a full ap­proval for Eli Lil­ly’s new Alzheimer’s drug do­nanemab, which will like­ly be a block­buster.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER